Novo Nordisk Inc. - חוב כולל להון NVO

The current total liabilities-to-equity ratio for Novo Nordisk A/S (NVO) on GURU.Markets demonstrates how the expansion of plants in the US and Europe supports high profitability. However, 0.66 represents the current metric value amid risks stemming from profit dependence on diabetes treatments. The stability of the structure is further complemented by the engagement of external partners for clinical trials and partial production.

For Novo Nordisk A/S (NVO), the debt-to-equity ratio reflects the balance between debt load and financial autonomy. This metric is calculated as the quotient of total liabilities divided by shareholder equity. It measures the extent to which financial leverage is utilized to scale the business. A low level of indebtedness allows the company to invest in environmental transformation and the recycling of medical devices. Such a capital structure ensures stability during the implementation of global ESG strategies.